clinical trial · NCT07223138
A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Psoriatic Arthritis
Arthritis, PsoriaticSonelokimab
brief summary
This is a study to demonstrate the long-term safety, tolerability and clinical efficacy of sonelokimab in the treatment of patients with psoriatic arthritis who completed a parental study (M1095-PSA-301 or M1095-PSA-302)
started
Nov 13, 2025
primary completion
Feb 4, 2028
completion
Feb 4, 2028
last updated
Jun 11, 2026
detailed description
M1095-PSA-303 is a Phase 3, multicenter, open-label extension study to investigate the long-term safety, tolerability and clinical efficacy of sonelokimab 60 mg subcutaneously every 4 weeks in patients with psoriatic arthritis who completed a parental study (M1095-PSA-301 or M1095-PSA-302).
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol